Market Intelligence, Clinical Progress, and High-Purity Reagents for Lysosomal Storage Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GM2A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GM2A Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View GM2A Products |
| Gene Delivery | GM2A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Optimized for expression validation. |
View GM2A Products |
| Benchmark Ab | Anti-GM2A Recombinant Antibody Recombinant positive control for assay development and ELISA validation. |
View GM2A Products |
| Validator | GM2A siRNA Set For knockdown verification and specificity controls in functional assays. |
View GM2A Products |
| Related Target A | HEXA Beta-hexosaminidase subunit alpha; partners with GM2A to degrade GM2 gangliosides. |
View HEXA Products |
| Related Target B | HEXB Beta-hexosaminidase subunit beta; crucial component of the hexosaminidase enzyme complex. |
View HEXB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation & Folding | HEK293 mammalian expression system preserves the native disulfide bonds and glycosylation patterns of GM2A. |
| Synergistic Complex Reconstitution | High-purity HEXA and HEXB proteins available for in vitro reconstitution of the GM2A-HexA-GM2 ganglioside complex. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included for assay standardization. |
| False Positives | Validated siRNA sets included for target knockdown and specificity verification in cell-based assays. |
Live GM2A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of GM2A (GM2 Ganglioside Activator) is gaining momentum across two main fronts: Enzyme Replacement Therapy (ERT)/Gene Therapy for lysosomal storage disorders (such as Tay-Sachs disease AB variant), and oncology, where GM2A overexpression is implicated in tumor progression and immune evasion. As first-generation gene therapies enter clinical evaluation, the next wave of R&D is targeting lipid-binding pocket modulation and bispecific constructs to restore or inhibit ganglioside catabolism.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / ERT | Sio Gene Therapies, Takeda | Tay-Sachs Disease, GM2 Gangliosidosis | Functional Reconstitution Assay (Requires high-purity GM2A and HEXA/HEXB proteins) |
| Monoclonal Antibody | Academic Institutions, Biotech Startups | Glioma, Melanoma, Solid Tumors | Epitope Mapping & Binding Affinity (Requires sequence-verified HEK293-expressed GM2A) |
| Small Molecule Modulators | Therapeutic Oligonucleotide Developers | Metabolic & Lysosomal Disorders | High-Throughput Screening (Requires stable GM2A-expressing lentiviral cell lines) |